Cimzia

Background

"This transaction demonstrates our ability to unlock unrecognized value in Nektar's legacy collaborations and access significant capital in a non-dilutive transaction. The proceeds from this sale will strengthen our cash position considerably and we are pleased to have Royalty Pharma as our partner in this transaction."

Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics

Applications in development

Psoriatic Arthritis

Therapeutic Area

Rheumatoid Arthritis
Crohn's Disease

Acquisition Date

Feb 2012

Marketer

Seller